PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) WO 97/35491 (51) International Patent Classification 6: (11) International Publication Number: A1 A23K 1/16 2 October 1997 (02.10.97) (43) International Publication Date: (81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, (21) International Application Number: PCT/SE97/00488 CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, 21 March 1997 (21.03.97) (22) International Filing Date: UA, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, (30) Priority Data: FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent 27 March 1996 (27.03.96) SE 9601197-8 (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, (71) Applicants (for all designated States except US): ASTAC-AROTENE AB [SE/SE]; Idrottsvägen 4, S-134 40 Gustavsberg (SE). SVENSKA FODER AB [SE/SE]; Kinnegatan 23, **Published** Box 673, S-531 16 Lidköping (SE). With international search report. (72) Inventors; and (75) Inventors/Applicants (for US only): LIGNELL, Åke [SE/SE]; Klippstigen 5, S-139 00 Varmdo (SE). INBORR, Johan [SE/SE]; Bäckvägen 27, S-531 55 Lidköping (SE). (74) Agents: NILSSON, Brita et al.; Oscar Grahn Patentbyra AB, P.O. Box 19540, S-104 32 Stockholm (SE).

(54) Title: AGENT FOR INCREASING THE PRODUCTION OF/IN BREEDING AND PRODUCTION MAMMALS

(57) Abstract

An agent for increasing the production of/in breeding and production mammals, which agent consists of at least one type of xanthophylles, is described. The preferred xanthophyll is astaxanthin. Moreover, a method of increasing the production of/in breeding and production mammals by administering an agent which consists of at least one type of xanthophylles, preferably astaxanthin, in the feed to animals is disclosed. Additionally, the use of the agent, preferably astaxanthin, for increasing the production of/in breeding and production mammals by administering said agent in the feed to said animals is disclosed.

BNSDOCID: <WO_____9735491A1_I_>

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL .	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	- Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvin	SZ	Swaziland
	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
AZ BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BE	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BF		HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BG	Bulgaria	IE	ireland	MN	Mongolia	UA	Ukraine
BJ	Benin	iL	Israel	MR	Mauritania	UG	Uganda
BR	Brazil	is	Iceland	MW	Malawi	US	United States of America
BY	Belarus	IT	Italy	MX	Mexico	UZ	Uzbekistan
CA	Canada	JP		NE	Niger	VN	Viet Nam
CF	Central African Republic		Japan Kanan	NL	Netherlands	YU	Yugoslavia
CG	Congo	KE	Kenya	NO	Norway	zw	Zimbabwe
CH .	Switzerland	KG	Kyrgyzstan		New Zealand		
a	Côte d'Ivoire	KP	Democratic People's	NZ			
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU -	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	Li	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
RE.	Estonia	LR	· Liberia	SG	Singapore		

BNSDOCID: <WO____9735491A1_I_>

AGENT FOR INCREASING THE PRODUCTION OF/IN BREEDING AND PRODUCTION MAMMALS.

5

10

The present invention relates to an agent for increasing the production of/in breeding and production mammals, to a method of increasing the production with said agent and the use of said agent. The agent consists of at least one type of xanthophylles, preferably naturally produced astaxanthin. It is administered in the feed to breeding and production animals to obtain increased production thereof.

Background

In the food, livestock, breeding animal and domestic animal industry the production of/in breeding and production animals is of great importance to the economy. Hence, there is a demand for agents that increase the productivity by for example improved fertility, more progeny born alive (especially pig, cow and sheep), lower mortality after birth, increased growth during the sucking period, higher milk production, shorter recovery period between weaning and new heat, and generally improved state of health due to strengthened immune defence.

The present invention now provides such an agent, which consists of at least one type of xanthophylles, preferably naturally produced astaxanthin

25

Astaxanthin belongs to the xanthophylles, which is a large group of carotenoids containing oxygen in the molecule in addition to carbon and hydrogen. The carotenoids are produced *de novo* by plants, fungi and some bacteria.

Xanthophylles have since long been used in the feed for laying hens and in some parts of the world in the feed for broilers, but not in the feed for breeding or production mammals. The purpose has solely been to pigment the product,

the yolk or fat and skin tissue, to satisfy the demands of the consumers. As sources for pigment both naturally produced xanthophylles and synthetically produced ones have been used (Hencken H., 1992, Poultry Science 71:711-717, Karunajeewa H. & A. Hoffman, 1992, Arch für Geflugelkunde 56(3):109-112).

Thus, it has not previously been known that xanthophylles, and among them astaxanthin, have the ability to increase the production of/in breeding and production mammals.

10

5

The reason for the improved productivity when astaxanthin enriched feed is used according to the present invention is not known, but it can be assumed to be due to the antioxidative properties of astaxanthin, and hence the ability to scavenge so-called free radicals. The other xanthophylles do also have antioxidative properties. However, in biological tests astaxanthin has been shown to possess clearly the best antioxidative properties compared to other carotenoids (Miki W., 1991, Pure and Appl Chem 63 (1): 141-146).

Description of the invention

20

15

The present invention thus provides an agent for increasing the production of/in breeding and production mammals, which agent consists of at least one type of xanthophylles.

25

30

Examples of breeding and production mammals are pigs, cattle, sheep, horses, dogs etc.

In a preferred embodiment the type of xanthophylles is astaxanthin. In a particularly preferred embodiment the astaxanthin exists in a form in which it is esterified with fatty acids. The last mentioned form of astaxanthin may be produced by cultivation of the alga Haematococcus sp.

The agent according to the invention may consist of a mixture of different types of xanthophylles or different forms of the same xanthophyll, such as a mixture of synthesized astaxanthin and naturally produced astaxanthin.

- The present invention further provides a method of increasing the production of/in breeding and production mammals, in which an agent, which consists of at least one type of xanthophylles, is administered in the feed to said mammals.
- In an embodiment of said method the type of xanthophyll is preferably
 astaxanthin. In a preferred embodiment of said method according to the
 invention, astaxanthin which exists in the form esterified with fatty acids, is
 administered. The amount of agent administered is suitably in the range of 1 to
 50 mg agent per kg feed.
- The present invention further comprises the use of an agent which consists of at least one type of xanthopylles for increasing the production of/in breeding and production mammals by administering said agent in the feed to said mammals.
- Also in this aspect of the invention the preferred type of xanthophyll is
 astaxanthin, which in a particularly preferred embodiment exists in a form
 esterified with fatty acids.

Description of experiments and preparation of the agent

The agent used in the experiments was the xanthophyll astaxanthin which was produced via algae, and the mammals used were pigs.

Astaxanthin from other sources, and other xanthophylles as well, are expected to be similarly useful for the purposes of the invention. An advantage of using astaxanthin from algae is, however, that the astaxanthin exists in a form esterified with fatty acids (Renström B. et al, 1981, Phytochem 20(11):2561-

5

10

2564), which esterified astaxanthin thereby is more stable during handling and storage than free astaxanthin.

The naturally produced astaxanthin can be obtained also from fungi and crustaceans, in addition to from algae. The astaxanthin used in the present test was produced via culturing of the algae Haematococcus sp. in the way described below.

Haematococcus sp. is a single-cell green algae belonging to the order Vovocales, family Chlamydomonadaceae. The reproduction takes normally place through asexual cell-division, but isogam sexual reproduction occures sporadically. When the alga is batch-cultivated it grows in the form of flagella-equipped so-called macrozoides. When the nutrient content of the medium decreases and becomes limiting for continuing growth, the cells lose the flagella and go into a palmella stage and form thereafter so-called haematocystes. They are characterized by a strong cell wall which encloses the cell, which in turn is rich in fatty vacuoles in which astaxanthin is accumulated. The haematocyst is a resting stage for the alga by which it can survive periods of dryness etc.

20

25

30

15

For the production a species or strain of Haematococcus sp. which grows fast and produces high titres of astaxanthin is suitably selected. A number of different species and strains of Haematococcus are available via so-called culture collections, and there is also the possibility of isolating a suitable strain from wild-growing populations. A suitable species is H. pluvialis which is available from NIVA, Norway.

Stock cultures of the algae are kept in axenic culture in a medium suitable therefore, see Table 1. The temperature should be approximately +25°C and the light intensity about 50 $\mu Em^{-2}S^{-1}$.

Table 1

Composition of growth medium for Haematococcus sp.

5	Ca(NO ₃)₂ x 4 H₂O	85 μM
	KH₂PO₄	91 μ M
	MgSO ₄ x 7 H₂O	203 μΜ
	NaHCO ₃	189 μΜ
	EDTA Na₂	7 μΜ
10	EDTA FeNa	6 μΜ
	H ₃ BO ₃	4 0 μ M
	MnCl ₂ x 4 H ₂ O	7 μ M
	(NH ₄) ₆ Mo ₇ O ₂₄ x 4 H ₂ O	0.8 μΜ
	Vitamin B ₁₂	10 μ g/ l
15	Vitamin B ₁	10 μg/l
	Biotin	10 μg/l
	NaNO ₃	940 μΜ
	NaH₂PO₄ x 12 H₂O	100 μΜ

- Inoculation material is taken from the stock cultures for the production culture. The cell density at inoculation is > 5000 cells/ml and the culture is reinoculated to a larger volume as the cell density reaches approximately 200 000 cells/ml, which will take approximately five days. At cultivation of the algal material the temperature is kept around +25°C and the light intensity should be approximately 100 μEm⁻²S⁻¹. The same composition of the medium is used as for the stock cultures. The cultures are agitated with compressed air which is enriched with 1 5 % CO₂. Alternatively, CO₂ may be added separately in such an amount that the pH value of the medium is kept between 6.5 8.5.
- When the volume of the algal culture reaches approximately 100 liters it is used for inoculation of a production unit, which consists of a device wherein the algal

cells can be exposed to light also when the culture volume may amount to 2 - 100 m³. Such a device may be designed as a shallow pond, a construction of transparent tubes, panels orientated against a source of light or alternatively, as in the example, a tank equipped with submerged lighting in the form of fluorescent lamps.

The production vessle is inoculated with a cell density of > 5000 cells/ml and the medium is enriched with nutrient salts in accordance with Table 1. The temperature is kept at approximately +25°C and the light intensity should be 100 $\mu\text{Em}^{-2}\text{S}^{-1}$. The culture is agitated with the aid of compressed air. Carbon dioxide is added to the culture so that the pH value will be between 6.5 - 8.5. When the nutrition in the medium begins to cease the algal cells turn over to the palmella stage and begin to synthesize astaxanthin. In this connection the light intensity is suitably increased to approximately 250 $\mu\text{Em}^{-2}\text{S}^{-1}$, the temperature to +30°C and NaCl is added to the medium so that a salt content of 0.1 - 0.3 % is obtained. These changes are made in order to accelerate the production of astaxanthin. In 10 - 20 days the cells have produced haematocysts and the cell density has increased to 5 - 10 x 10⁵ cells/ml.

- The cells are separated from the medium via sedimentation or via centrifugation. The harvested algal cells in the form of a paste are then passed through a homogenizer in order to brake the cell walls. The paste consisting of cells having broken cell walls may then be taken care of in two alternative ways. The paste may either be dried so that a dry powder is obtained. The drying should be done as leniently as possible so that the astaxanthin will not be degraded. An alternative to drying the paste is to extract the pigment from the paste. Since astaxanthin is highly hydrofobic the extraction can be made with a suitable oil, e.g. soy oil.
 - The amount of astaxanthin in the feed shuould preferrably been in the range of 1 50 mg astaxanthin/kg feed, and in the following experiments 5 mg astaxanthin/kg feed was used .

5

10

EXPERIMENT

The present experiment was conducted to investigate the effect of supplementing the sow diet with astaxanthin in 21 day period before parturition and during lactation on the growth rate of piglets weaned onto diets with or without astaxanthin supplementation.

MATERIALS AND METHODS

10

15

20

25

5

Experimental Design

A commercial sow feed was supplemented with (5 mg/kg) and without natural astaxanthin (Haematococcus pluvialis) and fed to pregnant sows to give two experimental treatments.

A total of 739 sows of parity two and above were divided into two experimental groups on the bases of parity and age. The sows were fed their respective experimental feeds from 35 days prior to farrowing, during lactation and until 21 days post weaning.

The number of born and stillborn piglets, and the number of piglets that died before weaning were recorded. In addition, the litter weight on day 21 after birth and the number of days between weaning and remating was recorded (Table 2). These measurements were also carried out during the subsequent parity (Table 3).

5

Table 2

Effect of natural astaxanthin (Haematococcus pluvialis) supplementation (5 mg/kg) of sow feed on sow performance.

	Treatment			
	Control	Astaxanthin 5 mg/kg	Significance (P=)	
Number of piglets born	10.43	10.65	0.139	
Percentage stillborn	8.76	8.08	0.919 ,	
Number of stillborn/litter	0.90	0.70	0.479	
Litter weight at	49.50	52.60	0.001	
21 days of age, kg				

^{*}The effect is statistically significant (P<0.05)

BNSDOCID: <WO_____9735491A1_I_>

Table 3

Performance of sows having received natural astaxanthin (Haematococcus pluvialis) during the preceding lactation period and 21 days post weaning.

Parity	Astaxanthin	FR (%)	WRMI, days	B.A.	S.B.P. (%)
2	•	93	10.30	10.7	7.4
	+	85	7.40	10.9	7.5
3	-	86	10.00	11.0	5.8
	+	83	8.20	9.4	6.1
4	-	81	11.0	10.3	11.1
	+	80	7.30	10.4	9.4
5	-	77	9.20	10.5	14.0
	+	73	7.70	9.8	14.0
Significance					
Astaxanthin (A)		0.211	0.004	0.461	0.786
Parity (P)		0.045°	0.366	0.119	0.001
A*P		0.927	0.740	0.769	0.906

^{*} The effect is statistically significant (P<0.5)

FR = Farrowing rate

WRMI = Weaning to remating interval

BA = Number of pigs born alive

SBP = Stillborn percentage

From the results presented above it can be concluded that naturally produced astaxanthin improves the performance of sows.

CLAIMS

- Agent for increasing the production of/in breeding and production mammals,
 characterized in that said agent consists of at least one type of xanthophylles.
 - 2. Agent according to claim 1, wherein the type of xanthophyll is astaxanthin.
- 3. Agent according to claim 2, wherein the astaxanthin exists in a form esterified with fatty acids.
 - 4. Agent according to claim 3, wherein the astaxanthin has been produced by culturing of the alga Haematococcus sp.
 - 5. Method of increasing the production of/in breeding and production mammals, characterized in that an agent which consists of at least one type of xanthophylles is administered in the feed to said mammals.
- 6. Method according to claim 5, wherein the type of xanthophyll is astaxanthin.
 - 7. Method according to claim 6, wherein the astaxanthin exists in a form esterified with fatty acids.
- 8. Method according to claim 6 or 7, wherein the amount of agent administered is in the range of 1 to 50 mg agent per kilogram feed.
 - 9. Use of an agent which consists of at least one type of xanthophylles for increasing the production of/in breeding and production mammals by administering said agent in the feed to said mammals.

30

10. Use according to claim 9, wherein the type of xanthophyll is astaxanthin.

11. Use according to claim 10, wherein the astaxanthin exists in a form esterified with fatty acids.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 97/00488

A. CLASSIFICATION OF SUBJECT MATTER								
1000 1000 1000								
IPC6: According	IPC6: A23K 1/16 According to International Patent Classification (IPC) or to both national classification and IPC							
B. FIELDS SEARCHED								
Minimum o	documentation searched (classification system followed	by classification symbols)	,					
IPC6:	A 23K							
		the cuted that and						
	ation searched other than minimum documentation to	the extent that such documents are included in	the fields searched					
SE,DK,	FI,NO classes as above							
Electronic d	data base consulted during the international search (na	me of data base and, where practicable, search	terms used)					
			•					
WPI. CI	LAIMS/US PATENTS, JAPIO, EPODOC,	CAPLUS						
	MENTS CONSIDERED TO BE RELEVANT							
Category*	<u> </u>							
- Category			Relevant to claim No.					
A	SE 503336 C2 (ASTA CAROTENE AB	ET AL),	1-11					
	20 March 1996 (20.03.96),	claims 1-11						
,	•							
			88					
		s I I I I						
		* 12						
			*					
			M.					
· [
		·						
Ì								
	:							
	r documents are listed in the continuation of Bo	X C. X See patent family annex	:.					
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "Beginning the general state of the art which is not considered to be of particular relevance "I later document published after the international filing date and not in conflict with the application but cited the principle or theory underlying the invention 								
'E' erlier doc	current but published on or after the international filing date	"X" document of particular relevance: the	claimed invention cannot be					
cited to e	t which may throw doubts on priority claim(s) or which is stablish the publication date of another citation or other	considered novel or cannot be considered step when the document is taken alone						
O" document	eason (as specified) t referring to an oral disclosure, use, exhibition or other	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is						
	t published prior to the international filing date but later than	being obvious to a person skilled in the	e art					
the priority date claimed "&" document member of the same patent family								
Date of the a	actual completion of the international search	Date of mailing of the international search report						
24 June	1997	10.07.97						
	nailing address of the ISA/	Authorized officer	 					
Swedish Pa	atent Office	·						
	5-102 42 STOCKHOLM b. + 46 8 666 02 86	Sofia Nikolopoulou						
	/210 (second sheet) (July 1992)	Telephone No. +46 8 782 25 00						

BNSDOCID: <WO_____9735491A1_i_>

INTERNATIONAL SEARCH REPORT

Information on patent family members

03/06/97

International application No.
PCT/SE 97/00488

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
SE 503336 C2	20/03/96	FI 971083 D NO 971051 A SE 9403147 A WO 9608977 A	00/00/00 07/03/97 20/03/96 28/03/96

Form PCT/ISA/210 (patent family annex) (July 1992)

THIS PAGE BLANK (URP